STAT3-IN-51
STAT3-IN-51 is a STAT3 inhibitor that directly binds to the STAT3 SH2 domain. STAT3-IN-51 induces apoptosis, ferroptosis, and immunogenic cell death (ICD) to potentiate anti-tumor immunity. STAT3-IN-51 inhibits STAT3 activation (phosphorylation, p-STAT3) and its downstream signaling. STAT3-IN-51 induces ROS generation, decreases Bcl-2 expression, disruptes mitochondrial function, suppresses GPX4 activity, and promotes lipid peroxidation. STAT3-IN-51 can be used for the study of colorectal carcinoma, breast adenocarcinoma, non-small cell lung cancer (NSCLC) and Cisplatin (HY-17394)-resistant pulmonary adenocarcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C36H27F6NO4
- 分子量:651.59
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
STAT3 |
GPX4 |
Bcl-2 |
STAT3-IN-51 (Compound 8d) (48 h) exhibits IC50 values of 0.26 μM, 0.34 μM, 0.61 μM, and 0.67 μM against SW480, MDA-MB-231, A549, and A549/DDP cells, respectively[1].
STAT3-IN-51 (0.3 μM; 24 h) induces apoptosis in SW480 cells through mitochondrial dysfunction and caspase activation[1].
STAT3-IN-51 (0.3 μM; 24 h) effectively inhibits both total STAT3 and p-STAT3 in SW480 cells[1].
STAT3-IN-51 (0.3 μM; 24 h) enhances CD8+ T lymphocyte infiltration and expansion[1].
STAT3-IN-51 (0.3 μM; 24 h) enhances dendritic cell maturation and reduces HMGB1 levels[1].
STAT3-IN-51 (0.3 μM; 24 h) induces ferroptosis in SW480 cells through GPX4 suppression and lipid peroxidation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SW480
-
Concentration:0.3 μM
-
Incubation Time:24 h
-
Result:Significantly reduced Bcl-2 expression, increased ROS generation, and induced mitochondrial depolarization. Flow cytometry showed a 8.37% and 30.3% increase in early and late apoptosis in SW480 cells.
-
Cell Line:SW480
-
Concentration:0.3 μM
-
Incubation Time:24 h
-
Result:Significantly suppressed both total STAT3 and p-STAT3 expression in SW480 cells, demonstrating dual inhibition of STAT3.
Significantly suppressed GPX4 expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c mice (5-week-old) bearing CT26 tumor xenografts[1]
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:i.p. (intraperitoneal); every two days for 13 days
-
Result:Achieved 63.17% tumor growth inhibition (TGI) at 5 mg/kg, and 75.62% TGI at 10 mg/kg.
At 10 mg/kg, shows better tolerability.
Had minimal toxicity, with no significant histopathological changes or weight loss.
化学情報
-
分子量 651.59
-
分子式 C36H27F6NO4
-
SMILES
O=C1C(C)=C(CCCC(N2C/C(C(/C(C2)=C/C3=CC=CC(C(F)(F)F)=C3)=O)=C\C4=CC=CC(C(F)(F)F)=C4)=O)C(C5=C1C=CC=C5)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
STAT3-IN-51 関連分類
HY-180245 関連分類
Powered by Bioz
- STAT3-IN-51
- STAT
- Ferroptosis
- Apoptosis
- Glutathione Peroxidase
- Bcl-2 Family
- Reactive Oxygen Species (ROS)
- STAT3 inhibitor
- apoptosis
- ferroptosis
- immunogenic cell death
- ROS generation
- decreases Bcl-2 expression
- disruptes mitochondrial function
- suppresses GPX4 activity
- colorectal carcinoma
- breast adenocarcinoma
- non-small cell lung cancer (NSCLC) and cisplatin-resistant pulmonary adenocarcinoma
- Inhibitor
- inhibitor
- inhibit